Avirulins, a Novel Class of HIV-1 Reverse Transcriptase Inhibitors Effective in the Female Reproductive Tract Mucosa.

Area of Science:

• Virology
• Medicinal Chemistry
• Immunology

Background:

• Antiretroviral therapy (ART) has reduced HIV transmissions and mortality.
• Drug resistance and heterosexual transmission pose ongoing challenges.
• Need for effective therapies in the female reproductive tract (FRT) mucosa.

Purpose of the Study:

• Screen a compound library for novel human immunodeficiency virus type 1 (HIV-1) inhibitors.
• Identify compounds effective against drug-resistant HIV-1 strains.
• Evaluate compound safety and efficacy in the FRT environment.

Main Methods:

• Screened 2095 small molecules against HIV-1 strain BaL.
• Tested identified inhibitors (Avirulins) against clinical HIV-1 isolates.
• Assessed inhibition of HIV-1 reverse transcriptase (RT).
• Evaluated cytotoxicity in FRT epithelial cells and activity in cervico-vaginal fluid.

Main Results:

• Identified Avirulins, a novel class of HIV-1 inhibitors.
• Avirulins active against diverse and drug-resistant HIV-1 strains.
• Demonstrated dose-dependent inhibition of HIV-1 RT, suggesting noncompetitive mechanism.
• Showed no significant toxicity in FRT cells and maintained activity in cervico-vaginal fluid.

Conclusions:

• Avirulins represent a promising new class of HIV-1 inhibitors.
• Effective against resistant strains and safe for the female reproductive tract.
• Potential chemical scaffolds for next-generation HIV-1 treatments and preventatives.